Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine ...

Retrieved on: 2021-11-04 14:43:10

Tags for this article:

Clinical medicine

Medicine

Monoclonal antibodies

Programmed cell death protein 1

PD-1 and PD-L1 inhibitors

Neuroendocrine tumor

Immunotherapy

Somatostatin receptor 2

Merkel

I Xencor Inc.

Xencor Inc.

Click the tags to see associated articles and topics

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine .... View article details on HISWAI: https://pipelinereview.com/index.php/2021110479597/Antibodies/Xencor-Presents-Clinical-Data-from-the-Phase-1-Study-of-Tidutamab-in-Neuroendocrine-Tumors-at-NANETS-Multidisciplinary-NET-Medical-Virtual-Symposium.html

Excerpt

(NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and ...

Article found on: pipelinereview.com

View Original Article